AP NEWS

Psoriasis Pipeline Report, H2 2018: Review of 150+ Companies & Drug Pipeline Activity - ResearchAndMarkets.com

September 24, 2018

DUBLIN--(BUSINESS WIRE)--Sep 24, 2018--The “Psoriasis - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Psoriasis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 14, 20, 40, 51, 122, 32 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 4 molecules, respectively.

Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Psoriasis - Overview Psoriasis - Therapeutics Development Psoriasis - Therapeutics Assessment Psoriasis - Companies Involved in Therapeutics Development Psoriasis - Drug Profiles Psoriasis - Dormant Projects Psoriasis - Discontinued Products Psoriasis - Product Development Milestones Appendix For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4chsw9/psoriasis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180924005347/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Psoriasis Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/24/2018 04:29 AM/DISC: 09/24/2018 04:29 AM

http://www.businesswire.com/news/home/20180924005347/en

AP RADIO
Update hourly